Recurrent endometrial, TNBC, and ovarian, primary peritoneal, or fallopian tube cancer. Biomarker enrolment: germline BRCA1/2-mutant, or BRCA1/2 wild-type cancers harboring somatic DDR or PI3K–AKT pathway alterations. This evidence concerns the gene BRCA1 and cancer.